Hutchmed Commences Phase III Trial of HMPL-306 For Patients with IDH1

Hutchmed (China), a biopharmaceutical firm, declares that it has started a registrational stage III clinical preliminary of HMPL-306 in patients with changed isocitrate dehydrogenase (IDH) 1 or 2 backslid/refractory intense myeloid leukemia (AML)...

Instylla Conclude Patient Enrollment in HES Hypervascular Tumour Pivotal Study

Instylla, Inc., a clinical-stage firm focused on creating fluid embolics for peripheral vascular embolotherapy, declared the completion of patient enlistment in the continuous Instylla HES Hypervascular Tumour Pivotal...

Moffitt Cancer Center and Fulgent Pharma Partner For Cancer Therapeutics

Moffitt Cancer Center, an incredibly famous cancer treatment and research center, and Fulgent Pharma, a nanobiotechnology firm, reported an essential organization pointed toward propelling cancer treatment through clinical turn of events and...

Fulcrum Therapeutics Ink pact with Sanofi To develop Losmapimod in FSHD

Fulcrum Therapeutics, Inc., a biotechnology firm declared that it has signed a collaboration and license agreement with Sanofi to develop and commercialize losmapimod, an oral small molecule being studied for the treatment of facioscapulohumeral...

Pharma Leaders to Explore New Technologies and Digital Innovations at AUTOMA+ 2024

Digital leaders and major players of the whole value chain gather at Pharmaceutical Automation and Digitalisation Congress (AUTOMA+ 2024) to share professional opinion on trends and latest solutions for the pharma digital transformation.

Zai Lab Bags China NMPA Nod of Augtyro To Treat Patients with NSCLC

Zai Lab Limited, a biotechnology firm, declared that the National Medical Products Administration (NMPA) in China has endorsed the New Drug Application (NDA) for Augtyro (repotrectinib) for the therapy of grown-up patients with privately...

Pharma Giant Sanofi To Fund over 1 Billion Euro in French Production Sites

Sanofi, a leading pharmaceutical and healthcare firm, reports a venture of more than €1 billion to establish a new bioproduction limit at its locales in Vitry-sur-Seine (Val de Marne), Le Quality (Seine-Oceanic) and Lyon Gerland (Rhône)...

Seagen's Tivdak Bags US FDA Nod To Treat Metastatic Cervical Cancer

The US Food and Drug Administration has granted full clearance to Seagen Inc.'s Tivdak (tisotumab vedotin), which targets tissue factor (TF), for the treatment of patients with recurrent or metastatic cervical cancer who have progressed during or...

Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg

Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Sevelamer Carbonate Tablets, 800 mg, from the USFDA

Intensity Therapeutics and SAKK Ink Pact To Conduct Phase 2 Trial

Intensity Therapeutics, Inc., a biotechnology firm, declares that the organization executed an alliance with The Swiss Group for Clinical Cancer Research (SAKK) to lead a stage 2 randomized (coordinated), controlled preliminary assessing clinical...

© 2025 India Pharma Outlook. All Rights Reserved.